<DOC>
	<DOCNO>NCT01124851</DOCNO>
	<brief_summary>The main purpose study evaluate safety tolerability drug ABT-652 give daily people excessive daytime sleepiness . Subjects randomized either ABT-652 placebo three sequential dose group 1-week treatment period .</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacokinetic Pharmacodynamic Study ABT-652 Subjects With Excessive Daytime Sleepiness</brief_title>
	<detailed_description />
	<mesh_term>Sleep Wake Disorders</mesh_term>
	<mesh_term>Parasomnias</mesh_term>
	<criteria>Inclusion Criteria Has current diagnosis excessive daytime sleepiness disorder , include narcolepsy , idiopathic hypersomnia , obstructive sleep apnea Age 18 60 year Exclusion Criteria Has significant suicidal ideation Has history substance abuse Has history certain significant medical condition , include uncontrolled psychiatric disease disorder Use certain medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Sleep disorder</keyword>
</DOC>